• Cancel
    Date：2023-03
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=710

    Qingdao PHAGEPHARM Biotechnology Co., Ltd. ("PHAGEPHARM" or “Company”), a leading domestic provider of phage-resistant comprehensive solutions, completed a Series B financing round of nearly RMB 100 million. This financing was led by Cenova Capital, with participation from Morningside Ventures and two existing shareholders. CEC Capital served as exclusive financial advisor for this transaction.

  • Cancel
    Date：2023-02
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=713

    NEXIC Technology, a company specializing in silicon carbide (SiC) power semiconductors, recently secured several hundred million yuan through its Series B and B+ financing rounds. The round was led by Xinchao Innovation Investment Group and JP Xinchao Cap

  • Cancel
    Date：2023-02

    Exclusive Financial Advisor to Concare

  • Cancel
    Date：2022-12
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=718

    OYMotion Technologies secured nearly RMB 100 million in its Series C funding round. The funding round was led by Intelligent Interconnection Industry Fund, a subsidiary of Qianhai Ark Industrial Fund, and Zhongyuan Qianhai Fund. XingTuo Capital, Zhang Y

  • Cancel
    Date：2022-12
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=719

    Sinovation (Beijing) Medical Technology Co., Ltd. (referred to as Sinovation), a leading Chinese intelligent platform for minimally invasive neurosurgery, recently announced the closing of nearly RMB 300 million in Series D financing. The round was led by

  • Cancel
    Date：2022-12
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=721

    BioMérieux recently entered a strategic investment partnership with Accunome Biotechnology Co., Limited ("Accunome"), which includes an equity investment and an exclusive distribution agreement. This partnership signifies a deep collaboration between BioM

  • Cancel
    Date：2022-12
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=720

    Ronovo Surgical (Shanghai) Medical Technology Co., Ltd. ("Ronovo Surgical” or “Ronovo") completes a financing round of tens of millions of dollars. The round was led by LongRiver Investments, with participation from existing investors including Lilly AsiaVentures, Vivo Capital, Matrix Partners China, GGV Capital, who continue to show strong confidence and support in the company's development. CEC Capital acted as the exclusive financial advisor for this financing round.

  • Cancel
    Date：2022-11

    Exclusive Financial Advisor to VIVEST

  • Cancel
    Date：2022-09
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=722

    Ubrigene (Beijing) Biology Technology Co., Ltd. (“Ubrigene”) has recently completed its Series C financing in the hundreds of millions RMB. The round was led by the National Strategic Transformation and Upgrading Fund under Jingshi Investment, Jingshi Kangjian Fund, and Lyon Capital's flagship China market USD fund. Also participating were Huada Gongying, Xing Investment Capital, Wenzhou Investment, Yuan Chuang Capital, as well as existing shareholders, including Huagai Capital, Fangfu Capital, and IDG Capital. CEC Capital served as the exclusive financial advisor to Ubrigene in this transaction.